Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Good day, everyone, and welcome to the Bebo's Therapeutics First Quarter 2026 Conference Call. At this time, all participants are in a listen-only mode. A question and answer session will follow management's remarks. This conference call is being recorded, and a replay of today's call will be available on the Investor Relations section of Bebo's website and will remain posted there for the next 30 days. I will now hand the call over to Brad Ammon, Chief Financial Officer, for introductions and a reading of the Safe Harvard Statement. Please go ahead. Thank you, Operator. Hello, everyone, and welcome to our conference call. A copy of our earnings release is available on the Investor Relations section of our website at www.vivos.com. With me on the call today is Kirk Huntsman, Vivos Chairman and Chief Executive Officer. Today, we'll review the financial results for the first quarter of 2026, as well as more recent developments and Vivos' plans for the rest of 2026 and beyond. Following these formal remarks, we'll be happy to take questions. I would also like to remind everyone that today's call will contain certain forward-looking statements from our management made within the meaning of Section 27A of the Securities Act of 1933 as amended in Section 21E of the Securities and Exchange Act of 1934 is amended concerning future events. Words such as aim, may, could, should, projects, expects, intends, plans, believes, anticipates, hopes, estimates, goal, and variations of such words and similar words regarding future events are intended to identify forward-looking statements. These statements involve significant known and unknown risks, and are based upon a number of assumptions and estimates which are inhe...